Published on | 4 months ago
Programmes MSCA MSCAThe European Research Executive Agency (REA) of the European Commission is conducting a survey to gather (anonymous) feedback on the added value of MSCA PhDs, in comparison to other doctoral programmes.
The survey is addressed to principal investigators/supervisors as well as PhD researchers (PhD completed or ongoing) involved in MSCA and non-MSCA funded projects.
This feedback is highly valuable as it will help to improve the MSCA Doctoral Networks programme, which is managed by the REA. It will also feed into the European Commission’s wider policy reflections for the forthcoming period: promoting excellence in doctoral education and training is relevant to their strategic objectives for both the European Research Area (ERA) and the European Education Area (EEA), and contributes to the implementation of the European Strategy for Universities (here and here) .
The survey can be accessed here and the Data Protection Notice here. Please note that it may take up to 1-2 minutes for the survey to load completely. The survey should take approximately 15 minutes to complete. The survey will remain open until 10 November 2024.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.